FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

被引：0

作者：

Moore, K. ^{[1
]}

Oza, A. ^{[2
]}

Colombo, N. ^{[3
,4
]}

Oaknin, A. ^{[5
]}

Scambia, G. ^{[6
]}

Lorusso, D. ^{[7
]}

Farias-Eisner, R. ^{[8
]}

Banerjee, S. ^{[9
]}

Murphy, C. ^{[10
]}

Tanyi, J. ^{[11
]}

Hirte, H. ^{[12
]}

Konner, J. ^{[13
]}

Lim, P. ^{[14
]}

Hayes, M. Prasad ^{[15
]}

Monk, B. ^{[16
]}

Kim, S. ^{[17
]}

Wang, J. ^{[18
]}

Pautier, P. ^{[19
]}

Vergote, I. ^{[20
]}

Birrer, M. ^{[21
]}

机构：

[1] Univ Oklahoma, Dept Obstet & Gynecol Univ, Stephenson Canc Ctr, Oklahoma City, OK USA

[2] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[3] European Inst Oncol, Dept Gynecol Oncol, Milan, Italy

[4] Univ Milano Bicocca, Milan, Italy

[5] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain

[6] Univ Cattolica, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy

[7] Fdn IRCCS Ist Nazl Tumori, Gynecol Oncol, Milan, Italy

[8] Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA

[9] Royal Marsden Hosp NHS Fdn Trust, Gynaecol, London, England

[10] Bon Secours Hosp, Med Oncol, Cork, Ireland

[11] Univ Penn, Obstet & Gynecol, Philadelphia, PA 19104 USA

[12] Juravinski Canc Ctr, Oncol, Hamilton, ON, Canada

[13] Mem Sloan Kettering Canc Ctr, Gynecol Oncol, 1275 York Ave, New York, NY 10021 USA

[14] Ctr Hope, Gynecol Oncol, Reno, NV USA

[15] Icahn Sch Med Mt Sinai, Obstet & Gynecol, New York, NY 10029 USA

[16] Creighton Univ, Univ Arizona, St Josephs Hosp, Gynecol Oncol,Arizona Oncol,Coll Med,Sch Med, Phoenix, AZ USA

[17] Univ Texas Houston, McGovern Med Sch, Houston, TX USA

[18] ImmunoGen Inc, Clin Dev, Waltham, MA USA

[19] Gustave Roussy, Med, Villejuif, France

[20] Univ Hosp Leuven Campus Gasthuisberg, Gynaecol, Leuven, Belgium

[21] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, MA USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

992O

引用

页数：1

共 50 条

[21] Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.
Moore, Kathleen N.
Martin, Lainie P.
Seward, Shelly Marie
Bauer, Todd Michael
O'Malley, David M.
Perez, Raymond P.
Oza, Amit M.
Jeong, Woondong
Kirby, Maurice William
Zhou, Yinghui
Michenzie, Mary F.
Ponte, Joseph
Ruiz-Soto, Rodrigo
Birrer, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[22] Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Moore, K. N.
Oza, A. M.
Colombo, N.
Oaknin, A.
Scambia, G.
Lorusso, D.
Banerjee, S.
Murphy, C.
Konner, J.
Lim, P.
Prasad-Hayes, M.
Monk, B. J.
Wang, J.
Birrer, M. J.
Vergote, I. B.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S790 - S791
[23] Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
Moore, Kathleen N.
O'Malley, David M.
Vergote, Ignace
Martin, Lainie P.
Gonzalez-Martin, Antonio
Malek, Karim
Birrer, Michael J.
GYNECOLOGIC ONCOLOGY, 2018, 151 (01) : 46 - 52
[24] FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.
Moore, Kathleen N.
Vergote, Ignace
Oaknin, Ana
Colombo, Nicoletta
Banerjee, Susana N.
Oza, Amit M.
Pautier, Patricia
Kelly, Catherine Margaret
Malek, Karim S.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[25] FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer
Moore, K. N.
Vergote, I.
Oaknin, A.
Colombo, N.
Banerjee, S.
Oza, A. M.
Pautier, P.
Kelly, C. M.
Malek, K.
Birrer, M. J.
ANNALS OF ONCOLOGY, 2017, 28
[26] Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Matulonis, Ursula A.
Lorusso, Domenica
Oaknin, Ana
Pignata, Sandro
Dean, Andrew
Denys, Hannelore
Colombo, Nicoletta
Van Gorp, Toon
Konner, Jason A.
Marin, Margarita Romeo
Harter, Philipp
Murphy, Conleth G.
Wang, Jiuzhou
Noble, Elizabeth
Esteves, Brooke
Method, Michael
Coleman, Robert L.
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2023, 78 (06) : 343 - 344
[27] Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Matulonis, Ursula A. A.
Lorusso, Domenica
Oaknin, Ana
Pignata, Sandro
Dean, Andrew
Denys, Hannelore
Colombo, Nicoletta
Van Gorp, Toon
Konner, Jason A. A.
Marin, Margarita Romeo
Harter, Philipp
Murphy, Conleth G. G.
Wang, Jiuzhou
Noble, Elizabeth
Esteves, Brooke
Method, Michael
Coleman, Robert L. L.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (13) : 2436 - +
[28] Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite
Tu, Ya-Ping
Hanze, Eva
Zhu, Fengying
Lagraauw, H. Maxime
Sloss, Callum M.
Method, Michael
Esteves, Brooke
Westin, Eric H.
Berkenblit, Anna
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (02) : 568 - 581
[29] Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study
Matulonis, Ursula
Lorusso, Domenica
Oaknin, Ana
Pignata, Sandro
Denys, Hannelore
Colombo, Nicoletta
Van Gorp, Toon
Konner, Jason
Romeo Marin, Margarita
Harter, Philipp
Murphy, Conleth
Wang, Jiuzhou
Noble, Elizabeth
Esteves, Brooke
Method, Michael
Coleman, Robert
GYNECOLOGIC ONCOLOGY, 2022, 166 : S50 - S50
[30] Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
Martin, Lainie P.
Konner, Jason A.
Moore, Kathleen N.
Seward, Shelly M.
Matulonis, Ursula A.
Perez, Raymond P.
Su, Ying
Berkenblit, Anna
Ruiz-Soto, Rodrigo
Birrer, Michael J.
GYNECOLOGIC ONCOLOGY, 2017, 147 (02) : 402 - 407

← 1 2 3 4 5 →